Cidara Therapeutics Inc (CDTX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Cidara Therapeutics Inc (CDTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8114
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:51
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cidara Therapeutics Inc (Cidara), formerly K2 Therapeutics Inc is a biotechnology company that discovers, develops and commercializes novel anti-infectives including immunotherapies. The company’s pipeline products include novel echinocandin CD101 IV, for the treatment of systemic candida infections; CD201, a bispecific antimicrobial immunotherapy that is being developed for multi-drug resistant bacterial infections, and others. The company develops cloudbreak, an immunotherapy platform, which helps to create compounds that direct a patient’s immune cells to strike and kill pathogens, which cause infectious diseases. Cidara is headquartered in San Diego, California, the US.

Cidara Therapeutics Inc (CDTX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Cidara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cidara Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cidara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cidara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cidara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cidara Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Cidara Therapeutics Acquires Intellectual Property for CD101 from Seachaid Pharma 11
Venture Financing 12
Cidara Therapeutics Raises USD42 Million in Series B Financing 12
Cidara Therapeutics Raises USD32 Million in Series A Venture Financing 14
K2 Therapeutics Raises USD30 Million in Venture Financing 16
K2 Therapeutics Raises USD6 Million in Venture Financing 17
Partnerships 18
Veristat Enters into Partnership with Cidara Therapeutics 18
Equity Offering 19
Cidara Therapeutics Plans to Raise up to USD68.7 Million in Public Offering of shares 19
Cidara Therapeutics to Raise USD50 Million in First Tranche Private Placement of Shares 20
Cidara Therapeutics Prices Private Placement of Shares for USD20 Million 22
Cidara Therapeutics Raises USD27.8 Million in Public Offering of Shares 23
Cidara Therapeutics Raises USD76.8 Million in Initial Public Offering of Shares 25
Cidara Therapeutics Inc – Key Competitors 27
Cidara Therapeutics Inc – Key Employees 28
Cidara Therapeutics Inc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Aug 08, 2018: Cidara provides corporate update and reports second quarter 2018 financial results 30
May 10, 2018: Cidara Provides Corporate Update and Reports First Quarter 2018 Financial Results 31
Feb 27, 2018: Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2017 Financial Results 32
Nov 08, 2017: Cidara Provides Corporate Update and Reports Third Quarter 2017 Financial Results 33
Aug 09, 2017: Cidara Provides Corporate Update and Reports Second Quarter 2017 Financial Results 35
May 10, 2017: Cidara Provides Corporate Update and Reports First Quarter 2017 Financial Results 36
Mar 15, 2017: Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results 37
Corporate Communications 38
Sep 12, 2018: Cidara Therapeutics names David Gollaher as bard director 38
Mar 01, 2018: Cidara Appoints Chrysa Mineo As Independent Director 39
Government and Public Interest 40
Sep 12, 2018: Celldom Awarded Phase II SBIR Grant to Advance Next Generation, High Throughput Single Cell Analysis Platform[Newswire : Healthcare-BW] 40
Product News 41
08/01/2017: Cidara Therapeutics Announces Publication of Results from In Vivo Study Investigating Novel Antifungal CD101 in Intra-Abdominal Candidiasis (IAC) 41
04/25/2017: Cidara Therapeutics Announces Promotion of Taylor Sandison, M.D., M.P.H., to Chief Medical Officer 42
04/17/2017: Cidara Therapeutics to Present Data on Cloudbreak Antibacterial Immunotherapy CD201 at ECCMID and SID Annual Meetings 43
04/17/2017: Cidara Therapeutics to Present Data on Novel Antifungal CD101 at ECCMID and SID Annual Meetings 44
03/30/2017: Cidara Therapeutics Awarded $6.9 Million Grant from CARB-X to Advance Development of its First Cloudbreak Antibiotic Immunotherapy 46
Clinical Trials 47
Sep 25, 2017: Cidara Therapeutics Announces Presentations at IDWeek 2017 and the 8th Trends in Medical Mycology Meeting 47
May 30, 2017: Cidara Therapeutics Announces Presentations at ASM Microbe 2017 and the 22nd Congress of the European Hematology Association 48
Feb 21, 2017: Cidara Therapeutics Reports Unfavorable Results of Phase 2 RADIANT Trial of CD101 Topical in VVC 49
Jan 04, 2017: Cidara Therapeutics Completes Enrollment in Phase 2 RADIANT Trial Evaluating Novel Antifungal CD101 Topical in Vulvovaginal Candidiasis 50
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51

List of Tables
Cidara Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Cidara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cidara Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cidara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cidara Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Cidara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cidara Therapeutics Acquires Intellectual Property for CD101 from Seachaid Pharma 11
Cidara Therapeutics Raises USD42 Million in Series B Financing 12
Cidara Therapeutics Raises USD32 Million in Series A Venture Financing 14
K2 Therapeutics Raises USD30 Million in Venture Financing 16
K2 Therapeutics Raises USD6 Million in Venture Financing 17
Veristat Enters into Partnership with Cidara Therapeutics 18
Cidara Therapeutics Plans to Raise up to USD68.7 Million in Public Offering of shares 19
Cidara Therapeutics to Raise USD50 Million in First Tranche Private Placement of Shares 20
Cidara Therapeutics Prices Private Placement of Shares for USD20 Million 22
Cidara Therapeutics Raises USD27.8 Million in Public Offering of Shares 23
Cidara Therapeutics Raises USD76.8 Million in Initial Public Offering of Shares 25
Cidara Therapeutics Inc, Key Competitors 27
Cidara Therapeutics Inc, Key Employees 28
Cidara Therapeutics Inc, Subsidiaries 29

List of Figures
Cidara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cidara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cidara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cidara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cidara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cidara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Cidara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cidara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Cidara Therapeutics Inc (CDTX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • F. Hoffmann-La Roche Ltd (ROG):医療機器:M&Aディール及び事業提携情報
    Summary F. Hoffmann-La Roche Ltd (Roche) is a biotechnology company, which develops drugs and diagnostics that improve the standard of care in major disease areas. It provides pharmaceuticals in cancer, neuroscience, infection, immunology, ophthalmology, cardiovascular and metabolism, hematology, ne …
  • Lycatel Services Ltd:企業の戦略的SWOT分析
    Lycatel Services Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Mediobanca – Banca di Credito Finanziario SpA (MB):企業の財務・戦略的SWOT分析
    Mediobanca - Banca di Credito Finanziario SpA (MB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • Toyota Tsusho Corporation:戦略・SWOT・企業財務分析
    Toyota Tsusho Corporation - Strategy, SWOT and Corporate Finance Report Summary Toyota Tsusho Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Marmen Inc:企業の戦略的SWOT分析
    Marmen Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • King Country Energy Ltd:企業の戦略的SWOT分析
    King Country Energy Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • UTStarcom Holdings Corp.:企業の戦略・SWOT・財務情報
    UTStarcom Holdings Corp. - Strategy, SWOT and Corporate Finance Report Summary UTStarcom Holdings Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Kansas Electric Power Cooperative, Inc.:企業の戦略的SWOT分析
    Kansas Electric Power Cooperative, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and m …
  • National Thermal Power Corporation Ltd:戦略・SWOT・企業財務分析
    National Thermal Power Corporation Ltd - Strategy, SWOT and Corporate Finance Report Summary National Thermal Power Corporation Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Credit Agricole CIB SA:企業の戦略的SWOT分析
    Credit Agricole CIB SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Yamato Holdings Co Ltd (9064):企業の財務・戦略的SWOT分析
    Yamato Holdings Co Ltd (9064) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Prism Cement Ltd:企業の戦略・SWOT・財務情報
    Prism Cement Ltd - Strategy, SWOT and Corporate Finance Report Summary Prism Cement Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Recondo Technology Inc:医療機器:M&Aディール及び事業提携情報
    Summary Recondo Technology Inc (Recondo) is a provider of cloud-based software and services that streamline operations in the healthcare industry. The company provides Empowered Patient Access, Empowered Business Office, and Empowered Technology solutions to connect providers with payers and their p …
  • Alphanosos SAS:製薬・医療:M&Aディール及び事業提携情報
    Summary Alphanosos SAS (Alphanosos) is a developer of novel therapies for the treatment of chronic inflammatory diseases. The company offers pure antibiofilms and antibiotics. It concentrates on bacterial biofilms in various therapeutic areas such as dermatological, bucco-dental and respiratory dise …
  • Skyworks Solutions Inc (SWKS):企業の財務・戦略的SWOT分析
    Skyworks Solutions Inc (SWKS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Jun Yang Financial Holdings Ltd:企業のM&A・事業提携・投資動向
    Jun Yang Financial Holdings Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Jun Yang Financial Holdings Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers …
  • Oiltanking GmbH:企業の戦略的SWOT分析
    Oiltanking GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Sumitomo Dainippon Pharma Co Ltd (4506):製薬・医療:M&Aディール及び事業提携情報
    Summary Sumitomo Dainippon Pharma Co Ltd (Sumitomo Dainippon), a subsidiary of Sumitomo Chemical Co., Ltd, develops manufacturers, purchases, sells, imports and exports pharmaceutical products. The company focuses on major therapeutic areas which include central nervous system (CNS), cardiovascular, …
  • Karlsruhe Institute of Technology:製薬・医療:M&Aディール及び事業提携情報
    Summary Karlsruhe Institute of Technology (KIT) is an educational service provider that offers research based scientific education. The institute offers research programs in the areas of biology, chemistry, and process engineering, mechanical and electrical engineering, physics and mathematics, natu …
  • Consejo Superior de Investigaciones Cientificas:製薬・医療:M&Aディール及び事業提携情報
    Summary Consejo Superior de Investigaciones Cientificas (CSIC) is a research institute that offers research capacity, and human and material resources to conduct research projects. The institute offers multidisciplinary scientific and technical research, scientific and technical advice, management o …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆